Patent: 10,017,762
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,017,762
Title: | Compositions and methods for treating or preventing lupus |
Abstract: | The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders. |
Inventor(s): | Rivera; Juan (Mechanicsburg, PA), Charles; Nicolas (Asnieres sur Seine, FR) |
Assignee: | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) |
Application Number: | 15/498,202 |
Patent Claims: | see list of patent claims |
Details for Patent 10,017,762
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2039-02-26 |
Glaxosmithkline Llc | BENLYSTA | belimumab | For Injection | 125370 | 03/09/2011 | See Plans and Pricing | 2039-02-26 |
Glaxosmithkline Llc | BENLYSTA | belimumab | Injection | 761043 | 07/20/2017 | See Plans and Pricing | 2039-02-26 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | See Plans and Pricing | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |